Bisphosphonates Combined with Vancomycin

Phase 3Small molecule

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Bisphosphonates Combined with Vancomycin is one of 43 small molecule programs targeting Osteomyelitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteomyelitisNot yet recruiting

OsteomyelitisPhase 3

Not yet recruiting

Competition

Competitive Landscape

43 competitors in Osteomyelitis

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Approved

1 2

Azulfidine

Pfizer

Approved

1 3

Mycobutin

Avelox

Biaxin

Maxipime

Zyvox

Priftin

Cipro

Acanya

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Not yet recruiting

Osteomyelitis

NCT07435051

Clinical

Trials by Indication[1]

Osteomyelitis1 trial

Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT07435051·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bisphosphonates Combined with Vancomycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bisphosphonates Combined with Vancomycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bisphosphonates Combined with Vancomycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Bisphosphonates Combined with Vancomycin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Osteomyelitis1 trial

References

Drug Info

Quick Facts

Related News